Bicara Therapeutics reports Q4 EPS (68c), consensus (65c)

As of December 31, 2025, Bicara had cash, cash equivalents and marketable securities of $414.8M, compared to $489.7M in cash and cash equivalents as of December 31, 2024. “Bicara enters the year with exceptional momentum across our clinical, regulatory, and corporate priorities,” said Claire Mazumdar, CEO at Bicara Therapeutics (BCAX). “The continued advancement of our pivotal FORTIFI-HN01 study, the robust body of clinical data supporting ficerafusp alfa’s differentiated profile, and the alternate dosing option for ficerafusp alfa all underscore the significant progress we’ve made toward transforming outcomes for patients with HPV-negative head and neck cancer. Coupled with our fortified financial position from our recent financing, we are well positioned to execute on our milestones, scale our organization for potential commercialization, if approved, and deliver meaningful value for patients and shareholders throughout the year.”